Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo rolls out Inavir dry powder Inhaler
Inavir is a long-acting neuraminidase inhibitor with therapeutic efficacy after a single dosage. Inavir shows the same efficacy with a single dose as a five-day administration of oseltamivir,
Inavir is a long-acting neuraminidase inhibitor with therapeutic efficacy after a single dosage. Inavir shows the same efficacy with a single dose as a five-day administration of oseltamivir,
Gilead posted a net income of $704.88m for the third quarter 2010, or $0.83 per diluted share, compared to $673.03m, or $0.72 per diluted share, for the comparable
Progenics has decided to implement Rave integrated with United BioSource Corp’s (UBC) interactive voice response system (IVRS) to manage a Phase III study evaluating methylnaltrexone, an opioid-induced constipation
Net profit was up by 30% to INR1708m from INR1319m last year. During the quarter, Zydus Cadila’s revenues were driven by 35% growth in the global formulations business,
Topical Interferon Alpha-2b incorporates Helix BioPharma’s proprietary Biphasix drug delivery technology, designed to offer a superior means of delivering interferon-alpha-2b therapeutically to HPV-infected tissues. Helix BioPharma said that
Aastrom intends to initiate Phase 3 clinical testing of its treatment for CLI in early 2011. Aastrom said that the designation may allow it to submit portions of
Altomari, a former senior manager at Johnson & Johnson, has been serving as Agile’s executive chairman. He will succeed Thomas Rossi, who joined Agile as president and CEO
Diamyd claims that NP2 Enkephalin is the first drug candidate from its proprietary NTDDS (Nerve Targeting Drug Delivery System)platform focally delivering therapeutic compounds directly to the nervous system.
Synairgen said that upon issuance, the patented claims will provide the company with patent protection for the use of its drug in the elderly population. Synairgen CEO Richard
Furthermore, Health Canada has advised that an inspection for the issue of an Establishment License has been scheduled over a number of days commencing 29 November 2010, following